Skip to content

Medical Properties Trust

US · MPT #2789 by market cap Listed 1970
3.23 -0.07 -2.12%
Live - 5344 symbols - heartbeat 422s ago · 2026-10-08 06:16
Pre-market 3.20 -0.93%
After-hours 3.24 +0.31%
Market cap
1.93B
P/B
0.43
EPS
-0.46
Reader sentiment Are you bullish or bearish on MPT?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 0.44 In line with history 33rd percentile
5-year average 0.58 · #2 of 19 in REIT - Healthcare Facilities
P/E ratio -66.00 Cheap vs history 7th percentile
5-year average -3.98 · forward 44.76
P/S ratio 1.93 Cheap vs history 12th percentile
5-year average 3.31 · forward 1.85 · #5 of 19 in REIT - Healthcare Facilities

Vs. peers REIT - Healthcare Facilities

Company Market cap P/E (TTM) P/B Div yield
Medical Properties Trust (MPT) 1.93B -64.60 0.43 10.84%
Welltower (WELL) 159.37B 101.90 3.43 1.34%
Healthpeak Properties (DOC) 12.87B 53.31 1.64 6.54%
American Healthcare REIT (AHR) 11.42B 72.60 3.09 2.03%
National Healthcare Properties (NHP) 1.12B -19.48 1.06 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value4.39 Economic moatNone UncertaintyMedium

Trading 36.0% below Morningstar's fair value estimate.

Fair value

Medical Properties Trust Inc receives a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 25% discount to our quantitative fair value estimate of $4.39 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 230.5% lies in the top 10% globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The company's balance sheet is an additional encouraging factor. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 1.5, a core component of leverage, ranks in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. This characteristic further promotes our favorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 06:16:11 · For reference only, not investment advice and not tailored to your situation.